drugset
drugset / Trial / NCT02552953

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

NCT02552953 ↗

Phase 1 Completed 60 enrolled Cyclacel Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, single arm, dose escalation study in patients with advanced cancers.

Timeline

Start
2015-09-28
Primary completion
2022-10-04
Completion
2023-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject CYC065 Small molecule — Other

Indications

cancer